169 related articles for article (PubMed ID: 36269747)
1. Identification of immune-related mechanisms of cetuximab induced skin toxicity in colorectal cancer patients.
Park JH; Kim MY; Choi IS; Kim JW; Kim JW; Lee KW; Kim JS
PLoS One; 2022; 17(10):e0276497. PubMed ID: 36269747
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study.
Wen F; Yang Y; Zhang P; Zhang J; Zhou J; Tang R; Chen H; Zheng H; Fu P; Li Q
Cancer Biol Ther; 2015; 16(11):1577-84. PubMed ID: 26418570
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial.
Nakamoto Y; Noda M; Mikami R; Tokunaga Y; Okumoto T; Kawamura T; Fujiwara H; Doi S; Tomita N
Int J Clin Oncol; 2020 Jul; 25(7):1285-1290. PubMed ID: 32200481
[TBL] [Abstract][Full Text] [Related]
4. Cytokine profile characterization of naïve patients with psoriasis and psoriatic arthritis: implications for a pathogenic disease continuum.
Ruscitti P; Esposito M; Di Cola I; Pellegrini C; De Berardinis A; Mastrangelo M; Gianneramo C; Barile A; Fargnoli MC; Cipriani P
Front Immunol; 2023; 14():1229516. PubMed ID: 37520537
[TBL] [Abstract][Full Text] [Related]
5. Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX).
Tougeron D; Emambux S; Favot L; Lecomte T; Wierzbicka-Hainaut E; Samimi M; Frouin E; Azzopardi N; Chevrier J; Serres L; Godet J; Levillain P; Paintaud G; Ferru A; Rouleau L; Delwail A; Silvain C; Tasu JP; Morel F; Ragot S; Lecron JC
Oncoimmunology; 2020 Nov; 9(1):1848058. PubMed ID: 33299659
[TBL] [Abstract][Full Text] [Related]
6. The clinical value of IL-3, IL-4, IL-12p70, IL17A, IFN-γ, MIP-1β, NLR, P-selectin, and TNF-α in differentiating bloodstream infections caused by gram-negative, gram-positive bacteria and fungi in hospitalized patients: An Observational Study.
Li X; Yuan X; Wang C
Medicine (Baltimore); 2019 Sep; 98(38):e17315. PubMed ID: 31568018
[TBL] [Abstract][Full Text] [Related]
7. Elevated Aqueous Cytokine Levels in Eyes With Ocular Surface Diseases.
Aketa N; Yamaguchi T; Asato T; Yagi-Yaguchi Y; Suzuki T; Higa K; Kurihara T; Satake Y; Tsubota K; Shimazaki J
Am J Ophthalmol; 2017 Dec; 184():42-51. PubMed ID: 28988898
[TBL] [Abstract][Full Text] [Related]
8. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
9. Cytokine and soluble programmed death-ligand 1 levels in serum and plasma of cancer patients treated with immunotherapy: Preanalytical and analytical considerations.
Cappelletto E; Fasiolo LT; Salizzato V; Piccin L; Fabozzi A; Contato A; Bianco PD; Pasello G; Chiarion-Sileni V; Gion M; Fabricio ASC
Int J Biol Markers; 2024 Mar; 39(1):9-22. PubMed ID: 38407953
[TBL] [Abstract][Full Text] [Related]
10. Panitumumab Provides Better Survival Outcomes Compared to Cetuximab for Metastatic Colorectal Cancer Patients Treated with Prior Bevacizumab within 6 Months.
Hayashi K; Mitani S; Taniguchi H; Yasui H; Muro K; Mori K; Gotoda T; Yamazaki K
Oncology; 2019; 96(3):132-139. PubMed ID: 30359979
[TBL] [Abstract][Full Text] [Related]
11. Oral mucositis associated with anti-EGFR therapy in colorectal cancer: single institutional retrospective cohort study.
Dote S; Itakura S; Kamei K; Hira D; Noda S; Kobayashi Y; Terada T
BMC Cancer; 2018 Oct; 18(1):957. PubMed ID: 30290786
[TBL] [Abstract][Full Text] [Related]
12. FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Kaiser F; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Miller-Phillips L; Modest DP; Jung A; Kirchner T; Stintzing S
Br J Cancer; 2021 Feb; 124(3):587-594. PubMed ID: 33154570
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
Stintzing S; Zhang W; Heinemann V; Neureiter D; Kemmerling R; Kirchner T; Jung A; Folwaczny M; Yang D; Ning Y; Sebio A; Stremitzer S; Sunakawa Y; Matsusaka S; Yamauchi S; Loupakis F; Cremolini C; Falcone A; Lenz HJ
Mol Cancer Ther; 2015 Oct; 14(10):2374-81. PubMed ID: 26206335
[TBL] [Abstract][Full Text] [Related]
14. Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
Stahler A; Heinemann V; Holch JW; von Einem JC; Westphalen CB; Heinrich K; Schlieker L; Jelas I; Alig AHS; Fischer LE; Weiss L; Modest DP; von Weikersthal LF; Decker T; Kiani A; Moehler M; Kaiser F; Kirchner T; Jung A; Stintzing S
Int J Cancer; 2021 Dec; 149(11):1935-1943. PubMed ID: 34310714
[TBL] [Abstract][Full Text] [Related]
15. Involvement of mannose receptor in cytokine interleukin-1beta (IL-1beta), IL-6, and granulocyte-macrophage colony-stimulating factor responses, but not in chemokine macrophage inflammatory protein 1beta (MIP-1beta), MIP-2, and KC responses, caused by attachment of Candida albicans to macrophages.
Yamamoto Y; Klein TW; Friedman H
Infect Immun; 1997 Mar; 65(3):1077-82. PubMed ID: 9038318
[TBL] [Abstract][Full Text] [Related]
16. Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19.
Körper S; Schrezenmeier EV; Rincon-Arevalo H; Grüner B; Zickler D; Weiss M; Wiesmann T; Zacharowski K; Kalbhenn J; Bentz M; Dollinger MM; Paul G; Lepper PM; Ernst L; Wulf H; Zinn S; Appl T; Jahrsdörfer B; Rojewski M; Lotfi R; Dörner T; Jungwirth B; Seifried E; Fürst D; Schrezenmeier H
Front Immunol; 2022; 13():1008438. PubMed ID: 36275695
[TBL] [Abstract][Full Text] [Related]
17. Cytokine and Chemokine Concentration in the Tear of Patients with Age-Related Cataract.
Engelbrecht C; Sardinha LR; Rizzo LV
Curr Eye Res; 2020 Sep; 45(9):1101-1106. PubMed ID: 31928443
[TBL] [Abstract][Full Text] [Related]
18. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
19. Profiling of inflammatory cytokines produced by gingival fibroblasts after human cytomegalovirus infection.
Botero JE; Contreras A; Parra B
Oral Microbiol Immunol; 2008 Aug; 23(4):291-8. PubMed ID: 18582328
[TBL] [Abstract][Full Text] [Related]
20. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
